Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 7/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.41 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3218241 | 0.88 | PTPN1 (0.42) | BACE1CYP3A4CYP1A2CYP2C8CYP2C9 | |
| SCHEMBL15349839 | 0.87 | LMNA (0.47) | BACE1CYP3A4CYP1A2CYP2C8CYP2C9 | |
| SCHEMBL3551620 | 0.83 | ALDH1A1 (0.51) | CYP3A4CYP1A2CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL34462800 | 0.83 | BACE1 (0.45) | BACE1CYP1A2ERN1CA1CA2 | |
| SCHEMBL3205905 | 0.83 | BACE1 (0.45) | BACE1CYP1A2ERN1CA1CA2 | |
| SCHEMBL743608 | 0.80 | ALDH1A1 (0.57) | BACE1CYP3A4ERN1CA1CA2 | |
| SCHEMBL20279251 | 0.80 | ERN1 (0.42) | BACE1CYP1A2CYP2C9CYP2C19ERN1 | |
| SCHEMBL20541205 | 0.80 | ALDH1A1 (0.52) | BACE1CYP1A2CYP2C9CYP2C19ERN1 | |
| SCHEMBL6683418 | 0.80 | ALDH1A1 (0.40) | BACE1ERN1TLR2TLR1TLR6 | |
| SCHEMBL12855017 | 0.80 | BACE1 (0.38) | BACE1CYP3A4CYP1A2CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023248174-A1 | AN IMPROVED PROCESS FOR PREPARATION OF VOXELOTOR | HETERO LABS LIMITED (IN) | 2023-12-28 | — | — | WO | claimed |
| WO-2023199345-A1 | NOVEL SOLID STATE FORMS OF VOXELOTOR AND THEIR PREPARATION METHODS THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2023-10-19 | — | — | WO | claimed |
| US-20250032471-A1 | Crystalline Polymorphs of the Free Base of 2-Hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | GLOBAL BLOOD THERAPEUTICS INC (US) | 2025-01-30 | — | — | US | disclosed |
| EP-3919056-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| EP-3102208-B2 | CRYSTALLINE POLYMORPH OF THE FREE BASE OF 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-115850040-B | Aromatic hydrocarbon monoacylation and bisacylation method | 江西亚太科技发展有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-115636742-B | Recrystallization method | 江西亚太科技发展有限公司 | 2024-04-09 | — | — | CN | disclosed |
| WO-2023248174-A1 | AN IMPROVED PROCESS FOR PREPARATION OF VOXELOTOR | HETERO LABS LIMITED (IN) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023199345-A1 | NOVEL SOLID STATE FORMS OF VOXELOTOR AND THEIR PREPARATION METHODS THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023199345-A1 | NOVEL SOLID STATE FORMS OF VOXELOTOR AND THEIR PREPARATION METHODS THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023199345-A1 | NOVEL SOLID STATE FORMS OF VOXELOTOR AND THEIR PREPARATION METHODS THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2023-10-19 | — | — | WO | disclosed |
| WO-2014150258-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014150258-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014145040-A1 | SUBSTITUTED ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014145040-A1 | SUBSTITUTED ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2013163244-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013163244-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-31 | — | — | WO | disclosed |
| EP-0054924-B1 | PHARMACEUTICAL COMPOUNDS, THEIR PREPARATION AND USE | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-08-06 | — | — | EP | disclosed |
| US-4535183-A | PALLIATION OF SICKLE CELL ANEMIA, RESPIRATORY DISORDERS, HYPOXIA, RADIOSENSITIZATION OF TUMORS | BURROUGHS WELLCOME CO. (US) | 1985-08-13 | — | — | US | disclosed |
| EP-0054924-A2 | Pharmaceutical compounds, their preparation and use | THE WELLCOME FOUNDATION LIMITED (GB) | 1982-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032471-A1 | Crystalline Polymorphs of the Free Base of 2-Hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | H1-0, INF2, H1-2 | BACE1 3422/4885CYP3A4 761/4885CYP1A2 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.